Skip to content
10-K

Annual Report

Zenas BioPharma, Inc. ZBIO

0001558370-25-002631

← back to feed
Filed
Mar 11, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 28, 2025 41.8M sh
Shares Diluted FY 2024 · Dec 31, 2023 1.53M sh
Capex FY 2024 · Dec 31, 2023 $17K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$30.53M
Cash And Equivalents FY 2024 · Dec 31, 2023 $56.86M
Current Liabilities FY 2024 · Dec 31, 2023 $23.26M
Total Liabilities FY 2024 · Dec 31, 2023 $43.82M
Current Assets FY 2024 · Dec 31, 2023 $59.8M
Total Assets FY 2024 · Dec 31, 2023 $68.18M
Eps Diluted FY 2024 · Dec 31, 2023 −$24.25
Eps Basic FY 2024 · Dec 31, 2023 −$24.25
Sga Expense FY 2024 · Dec 31, 2023 $17.11M
Rd Expense FY 2024 · Dec 31, 2023 $60.03M
Net Income FY 2024 · Dec 31, 2023 −$37.12M
Operating Income FY 2024 · Dec 31, 2023 −$37.15M
Revenue FY 2024 · Dec 31, 2023 $50M
Stockholders Equity FY 2024 · Dec 31, 2022 −$192.29M